Thrombin Inhibitor

Dabigatran acyl-β-D-glucuronide is an active metabolite of the thrombin inhibitor Dabigatran (HY-10163). Dabigatran acyl-β-D-glucuronide increases activated partial thromboplastin time (aPTT) in isolated human platelet-poor plasma.

Dabigatran etexilate (mesylate) (Standard) is the analytical standard of Dabigatran etexilate (mesylate). This product is intended for research and analytical applications. Dabigatran etexilate mesylate (BIBR 1048MS) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate mesylate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation.

Thrombin Inhibitor 2 (Standard) is the analytical standard of Thrombin Inhibitor 2 (HY-10217). This product is intended for research and analytical applications. Thrombin Inhibitor 2 is a small molecule direct thrombin inhibitor, extracted from US8541580B2. Thrombin Inhibitor 2 has antithrombotic activity.

Bacithrocin C is a thrombin inhibitor that inhibits thrombin, factor Xa, trypsin and Papain with IC₅₀s of 80 μM, 15 μM, 1.3 μM, and 0.02 μM, respectively.

BMS-189664 hydrochloride is a potent, selective, and orally active reversible inhibitor of a-thrombin, with an IC₅₀ of 0.046 μM. BMS-189664 hydrochloride can be used for arterial and venous thrombosis research.

Odiparcil (Standard) is the analytical standard of Odiparcil (HY-10277). This product is intended for research and analytical applications. Odiparcil (SB-424323) is an orally active β-D-xyloside derivative. Odiparcil can effectively divert the synthesis of cellular glycosaminoglycans (GAG) into secreted soluble species and reduce GAG accumulation. Odiparcil shows antithrombin and antiplatelet activity. Odiparcil can be used for the researches of metabolic and cardiovascular disease, such as mucopolysaccharidoses (MPS) and thrombosis.

BMS-189664 is a potent, selective, and orally active reversible inhibitor of a-thrombin, with an IC₅₀ of 0.046 μM. BMS-189664 can be used for arterial and venous thrombosis research.

SC42619 free base is a selective platelet thrombin receptor (thrombin receptor) antagonist. SC42619 free base inhibits thrombin-induced platelet aggregation, secretion, calcium influx, and phosphatidic acid phosphorylation, as well as trypsin-induced platelet aggregation. SC42619 free base reduces the content of individual platelets. SC42619 free base inhibits prostacyclin (PGI₂) synthesis in endothelial cells. SC42619 free base can be used for the research of hematological diseases.

Moxicoumone is an anticoagulant.

5-((1H-Indol-3-yl)methylene)imidazolidine-2,4-dione is an inhibitor of dengue virus NS2B-NS3 protease and thrombin. 5-((1H-Indol-3-yl)methylene)imidazolidine-2,4-dione can be used in the research of infectious diseases.

GYKI-14451 sulfate is an inhibitor of thrombin and plasmin. GYKI-14451 sulfate inhibits thrombin-fibrinogen and plasmin-fibrin reactions. GYKI-14451 sulfate inhibits fibrin clot lysis and prolongs fibrin clot lysis time in a dose-dependent manner. GYKI-14451 sulfate does not undergo N-terminal cyclization and spontaneous inactivation in neutral aqueous buffer. GYKI-14451 sulfate can be used in studies related to venous thrombosis and fibrinogen solidification.

Napsagatran (Ro 46-6240) hydrate is a potent thrombin inhibitor. Napsagatran hydrate exhibits anticoagulant effects in vitro and in vivo. Napsagatran hydrate can be used in antithrombotic research^[1][2].

Inogatran (H-314-27) is a synthetic thrombin inhibitor, developed for the possible treatment and prophylaxis of arterial and venous thrombotic diseases.

Atecegatran (AR-H067637) is an orally active competitive thrombin inhibitor with a K_i of 2-4 nM. AR-H067637 inhibits platelet activation and aggregation by blocking thrombin binding to fibrin and thrombomodulin. Atecegatran demonstrates significant anticoagulant effects in various plasma coagulation assays, with an IC₅₀ ranging from 93 to 220 nM. Atecegatran can be used in research related to thromboembolic disorders.

Flovagatran (TGN 255) sodium is a potent and reversible thrombin inhibitor (K_i: 9 nM). Flovagatran sodium can be used in the research of arterial and venous thrombosis.

Isovanillic acid (3-Hydroxy-4-methoxybenzoic acid) is a phenolic acid isolated from isolated from Scrophularia ningpoensis, with anti-thrombotic activity.

Bacithrocin B is a thrombin inhibitor that inhibits thrombin, factor Xa, trypsin and Papain with IC₅₀s of 84 μM, 17 μM, 1.7 μM, and 0.02 μM, respectively.

FXIIa-IN-1-IN-2 (Compound 21) is a Factor XIIa inhibitor (K_i^app: 62.2 nM). FXIIa-IN-1-IN-2 can be used for research of thrombosis.

Propacetamol (hydrochloride) (Standard) is the analytical standard of Propacetamol (hydrochloride). This product is intended for research and analytical applications. Propacetamol hydrochloride is a potent, peptidic inhibitor targeting thrombin and granzyme GZMK. Propacetamol hydrochloride specifically blocks the activities of thrombin and GZMK, thereby inhibiting thrombin-mediated PAR-1 cleavage, as well as downstream inflammatory and procoagulant signaling pathways. Through stabilizing IκB proteins, blocking NF-κB activation and reducing systemic levels of proinflammatory/procoagulant biomarkers, Propacetamol hydrochloride exerts multiple effects including anti-inflammatory, antithrombotic, barrier repair, and inhibition of atherosclerotic plaque progression. Propacetamol hydrochloride binds to platelets without interference from kininogen, effectively limiting acute thrombus growth and reducing eosinophil infiltration and goblet cell hyperplasia in asthma models. Propacetamol hydrochloride is an important tool molecule for investigating the mechanisms of atherosclerosis, asthma and related thromboinflammatory diseases.

Pirmagrel is a thrombin synthetase inhibitor. Pirmagrel has inhibitory effects on thrombin secretion stimulated by lipopolysaccharide (HY-D1056).